You are here: Industry Insights > CRSwNP

News List

GSK’s Nucala approved to treat chronic rhinosinusitis with nasal polyps pharmatimes
August 02, 2021
GlaxoSmithKline’s (GSK) interleukin-5 (IL-5) inhibitor has received approval from the US Food and Drug Administration (FDA) for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP).
Fasenra Meets Co-Primary Endpoints americanpharmaceuticalreview
September 17, 2020
High-level results from the OSTRO Phase III trial showed AstraZeneca’s Fasenra (benralizumab) compared with placebo demonstrated a statistically significant improvement in the size of nasal polyps and in nasal blockage in patients with chronic ...
European Commission approves Novartis’ Xolair® (omalizumab) europeanpharmaceuticalreview
August 10, 2020
Novartis’ Xolair (omalizumab) has been approved by the European Commission as an add-on therapy with intranasal corticosteroids to treat severe chronic rhinosinusitis with nasal polyps.
EU approves new indication for Novartis’ Xolair pharmatimes
August 07, 2020
The European Commission has approved a new indication for Novartis’ Xolair (omalizumab) as an add-on therapy for the treatment of adults with sever chronic rhinosinusitis with nasal polyps (CRSwNP).
FDA Approves Dupixent (dupilumab) for Chronic Rhinosinusitis with Nasal Polyposis drugs
June 27, 2019
FDA Approves Dupixent (dupilumab) for Chronic Rhinosinusitis with Nasal Polyposis.
Sanofi/Regeneron’s Dupixent shows more promise in nasal polyps pharmaphorum
February 27, 2019
Sanofi and Regeneron’s attempts to make Dupixent into a blockbuster franchise have been boosted with more strong phase 3 results in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).
Sanofi, Regeneron’s Dupixent shines in rhinosinusitis with nasal polyps trials pharmatimes
November 01, 2018
Sanofi and Regeneron have unveiled top-line data showing that two late-stage studies of Dupixent in adults with inadequately-controlled chronic rhinosinusitis with nasal polyps (CRSwNP) met all ...